Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.

ABSTRACT: Rasagiline is a monoamine oxidase type B inhibitor that possesses no amphetamine-like properties, and provides symptomatic relief in early and late stages of Parkinson's disease (PD). Data in animal models of PD suggest that chronic administration of rasagiline is associated with structural changes in the substantia nigra, and raise the question whether the structure and function of the basal ganglia could be different in PD patients treated chronically with rasagiline as compared with PD patients not treated with rasagiline. Here, we performed a retrospective cross-sectional magnetic resonance imaging (MRI) study at 3 T that investigated nigrostriatal function and structure in PD patients who had taken rasagiline before testing (∼8 months), PD who had not taken rasagiline before testing,

SUBMITTER: Burciu RG 

PROVIDER: S-EPMC4945383 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature